weight gain after semaglutide Regain Stopping Semaglutide: Evidence-Based Appro... – PlexusDx In the original clinical trials

Researchers estimated that semaglutide could cut the obesity prevalence in the United States by about 46% and prevent more than 1.5 million CVD events over 10 years when given to eligible patients with overweight or obesity

CureSearchs mission is to end childhood cancer by driving targeted and innovative research with measurable results in an accelerated time frame

On March 18, 2026, the FDA released a landmark draft guidance: "General Considerations for the Use of New Approach Methodologies (NAMs) in Drug Development." For small-to-midsize biotechs, this isn't just about ethicsits about capital efficiency and regulatory speed

The risk of major adverse cardiovascular events was significantly reduced after one year (HR 0.70) and remained lower at two years (HR 0.79)